Gilder Gagnon Howe & Co. LLC Has $487,000 Position in Sarepta Therapeutics, Inc. (SRPT)
Gilder Gagnon Howe & Co. LLC cut its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.5% during the second quarter, Holdings Channel reports. The firm owned 14,437 shares of the biotechnology company’s stock after selling 222 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in Sarepta Therapeutics were worth $487,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Prentiss Smith & Co. Inc. boosted its stake in shares of Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 3,166 shares during the period. Ameritas Investment Partners Inc. purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at $127,000. PNC Financial Services Group Inc. boosted its stake in shares of Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 2,800 shares during the period. Edge Wealth Management LLC purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at $175,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at $209,000. 64.58% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics, Inc. (NASDAQ SRPT) opened at 37.02 on Friday. Sarepta Therapeutics, Inc. has a 52-week low of $24.31 and a 52-week high of $63.73. The company has a 50-day moving average of $36.95 and a 200-day moving average of $32.78. The stock’s market capitalization is $2.38 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million during the quarter, compared to analyst estimates of $22.52 million. During the same period in the prior year, the business earned ($1.19) earnings per share. Sarepta Therapeutics’s quarterly revenue was up 350000.0% on a year-over-year basis. Equities research analysts expect that Sarepta Therapeutics, Inc. will post ($1.16) EPS for the current year.
Several analysts recently weighed in on the stock. BidaskClub cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. William Blair reaffirmed an “outperform” rating on shares of Sarepta Therapeutics in a report on Thursday, July 27th. Zacks Investment Research raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. Morgan Stanley reaffirmed an “equal weight” rating and issued a $31.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 30th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $50.00 target price on shares of Sarepta Therapeutics in a report on Thursday, July 20th. Eight research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $61.28.
In other Sarepta Therapeutics news, SVP Alexander Cumbo sold 5,918 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $242,638.00. Following the sale, the senior vice president now directly owns 22,793 shares of the company’s stock, valued at $934,513. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Douglas S. Ingram bought 47,058 shares of the company’s stock in a transaction on Thursday, July 27th. The stock was bought at an average cost of $42.50 per share, for a total transaction of $1,999,965.00. Following the completion of the transaction, the chief executive officer now directly owns 382,058 shares of the company’s stock, valued at $16,237,465. The disclosure for this purchase can be found here. Insiders sold 78,056 shares of company stock worth $3,224,208 over the last ninety days. 9.60% of the stock is owned by corporate insiders.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.